Related Experiment Video
Updated: Aug 15, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Accurate Collection of Reasons for Treatment Discontinuation to Better Define Estimands in Clinical Trials
Yongming Qu1, Robin D White2, Stephen J Ruberg3
1Department of Global Statistical Sciences, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. qu_yongming@lilly.com.
Background:
Reasons for treatment discontinuation are important not only to understand the benefit and risk profile of experimental treatments, but also to help choose appropriate strategies to handle intercurrent events in defining estimands. The current case report form (CRF) commonly in use mixes the underlying reasons for treatment discontinuation and who makes the decision for treatment discontinuation, often resulting in an inaccurate collection of reasons for treatment discontinuation.
Methods And Results:
We systematically reviewed and analyzed treatment discontinuation data from nine phase 2 and phase 3 studies for insulin peglispro. A total of 857 participants with treatment discontinuation were included in the analysis. Our review suggested that, due to the vague multiple-choice options for treatment discontinuation present in the CRF, different reasons were sometimes recorded for the same underlying reason for treatment discontinuation. Based on our review and analysis, we suggest an intermediate solution and a more systematic way to improve the current CRF for treatment discontinuations.
Conclusion:
This research provides insight and directions on how to optimize the CRF for recording treatment discontinuation. Further work needs to be done to build the learning into Clinical Data Interchange Standards Consortium standards.
Clinical Trials:
Clinicaltrials.gov numbers: NCT01027871 (Phase 2 for type 2 diabetes), NCT01049412 (Phase 2 for type 1 diabetes), NCT01481779 (IMAGINE 1 Study), NCT01435616 (IMAGINE 2 Study), NCT01454284 (IMAGINE 3 Study), NCT01468987 (IMAGINE 4 Study), NCT01582451 (IMAGINE 5 Study), NCT01790438 (IMAGINE 6 Study), NCT01792284 (IMAGINE 7 Study).
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Kaplan-Meier Approach
Assumptions of Survival Analysis
Truncation in Survival Analysis
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are observed.
